Pharma News

14 August 2025

Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments

Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals with Galibra Neuroscience and Emugen Therapeutics to utilize Apertura’s human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs. A third venture-backed biotechnology company has entered into an Option Agreement with Apertura for multiple CNS indications.

14 August 2025

AAVantgarde Bio announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

AAVantgarde Bio a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for AAVB-039, the companys gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4

13 August 2025

Anixa Biosciences secures New U.S. Patent extending CAR-T Cancer Therapy Protection to 2045

Anixa Biosciences, Inc., a clinical-stage biotechnology company specializing in cancer treatment and prevention, has announced the issuance of a new U.S. patent for its chimeric antigen receptor-T cell (CAR-T) technology.

13 August 2025

Zydus Lifesciences delivers steady growth in Q1 FY26, boosted by global expansion

Zydus Lifesciences Limited reported a steady performance for the quarter ended June 30, 2025, with growth across key geographies and strong contributions from innovation-driven initiatives. The pharmaceutical major posted revenue from operations of Rs. 65,737 million, marking a 6% increase year-on-year and a marginal 0.7% rise from the previous quarter. Net profit stood at Rs. 14,668 million, up 3% from the same quarter last year and a robust 25.3% higher than Q4 FY25.

13 August 2025

Indoco Remedies receives final ANDA approval from USFDA for Rivaroxaban Tablets

Indoco Remedies Ltd. announced final approval of the Company Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg, to market a generic equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen), from USFDA.

13 August 2025

Padcev™ plus keytruda™ significantly improves survival for certain patients with bladder cancer when given before and after surgery

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905).

13 August 2025

Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquats KRAS G12D inhibitor.

8 August 2025

Valneva announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ®

Valneva SE announced that the FDA has removed its recommended pause in the use of IXCHIQ in individuals 60 years of age and older and has approved updates to the Prescribing Information for IXCHIQ.

8 August 2025

Cormedix to acquire Melinta Therapeutics

CorMedix Inc. a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC, a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses announced a definitive agreement for CorMedix to acquire Melinta.

5 August 2025

LENZ Therapeutics announces USFDA approval of VIZZ for the Treatment of Presbyopia

LENZ Therapeutics, Inc announced the US Food and Drug Administration approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities to be initiated immediately.

Search

Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments

RECOMMENDED POSTS

Subscribe with us

Jobs by Category